IL93219A - Pharmaceutical compositions for treating leukocyte dysfunction containing gm-csf - Google Patents

Pharmaceutical compositions for treating leukocyte dysfunction containing gm-csf

Info

Publication number
IL93219A
IL93219A IL9321990A IL9321990A IL93219A IL 93219 A IL93219 A IL 93219A IL 9321990 A IL9321990 A IL 9321990A IL 9321990 A IL9321990 A IL 9321990A IL 93219 A IL93219 A IL 93219A
Authority
IL
Israel
Prior art keywords
csf
treating
composition
dysfunction
leukocyte
Prior art date
Application number
IL9321990A
Other languages
English (en)
Other versions
IL93219A0 (en
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL93219A0 publication Critical patent/IL93219A0/xx
Publication of IL93219A publication Critical patent/IL93219A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • External Artificial Organs (AREA)
IL9321990A 1989-01-30 1990-01-30 Pharmaceutical compositions for treating leukocyte dysfunction containing gm-csf IL93219A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30439189A 1989-01-30 1989-01-30

Publications (2)

Publication Number Publication Date
IL93219A0 IL93219A0 (en) 1990-11-05
IL93219A true IL93219A (en) 1998-12-27

Family

ID=23176323

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9321990A IL93219A (en) 1989-01-30 1990-01-30 Pharmaceutical compositions for treating leukocyte dysfunction containing gm-csf

Country Status (21)

Country Link
US (1) US5178855A (de)
EP (2) EP0455726A1 (de)
JP (1) JPH0651640B2 (de)
KR (1) KR0137361B1 (de)
AT (1) ATE89737T1 (de)
AU (1) AU633054B2 (de)
CA (1) CA2045605C (de)
DE (1) DE69001686T2 (de)
DK (1) DK0382381T3 (de)
ES (1) ES2055314T3 (de)
FI (1) FI913625A0 (de)
HK (1) HK46196A (de)
HU (1) HU207229B (de)
IE (1) IE64234B1 (de)
IL (1) IL93219A (de)
MY (1) MY105798A (de)
NZ (1) NZ243953A (de)
OA (1) OA09509A (de)
PT (1) PT92995B (de)
WO (1) WO1990008554A1 (de)
ZA (1) ZA90600B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI924778A0 (fi) * 1991-02-22 1992-10-21 Amgen Inc Anvaendning av gm-csf och g-csf foer foersnabbande av saorlaekning
GB9120304D0 (en) * 1991-09-24 1991-11-06 Erba Carlo Spa Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor
WO1994028919A1 (fr) * 1993-06-08 1994-12-22 Ajinomoto Co., Inc. Accelerateur de la proliferation des cellules hematopietiques
WO1995023862A1 (en) * 1994-03-04 1995-09-08 Ludwig Institute For Cancer Research Animals with targeted gene disruption
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
JP2010513525A (ja) * 2006-12-22 2010-04-30 ノヴァデル ファーマ インコーポレイテッド 安定な抗嘔吐経口噴霧製剤および方法
US7648379B2 (en) 2007-08-09 2010-01-19 Haworth, Inc. Modular electrical distribution system for a building

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
JPS63502795A (ja) * 1985-10-03 1988-10-20 バイオジェン インコーポレイテッド 顆粒球‐マクロファージコロニー刺激因子‐様ポリペプチド、ｄｎａ配列、組換えｄｎａ分子並びに微生物細胞中でヒト顆粒球−マクロファ−ジコロニ−刺激因子−様ポリペプチドを高収量で生産する方法
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤
US4921837A (en) * 1985-11-27 1990-05-01 Genetics Institute Inc. Treatment of AIDS-type disease
JP2579981B2 (ja) * 1986-05-06 1997-02-12 ジェネティックス・インスチチュート・インコーポレーテッド Ｍ―ｃｓｆの生産方法
US5162111A (en) * 1986-07-30 1992-11-10 Grabstein Kenneth H Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor
EP0276846A3 (de) * 1987-01-29 1989-07-26 Zymogenetics, Inc. Derivate des koloniestimulierenden Faktors
IL88344A (en) * 1987-11-12 1994-06-24 Schering Corp Accelerating bone formation using a factor that accelerates colonies of granulocyte macrophages

Also Published As

Publication number Publication date
CA2045605C (en) 1997-02-11
DK0382381T3 (da) 1993-07-12
EP0382381A1 (de) 1990-08-16
HU207229B (en) 1993-03-29
HUT57607A (en) 1991-12-30
IL93219A0 (en) 1990-11-05
PT92995B (pt) 1995-12-29
OA09509A (en) 1992-11-15
CA2045605A1 (en) 1990-07-31
AU633054B2 (en) 1993-01-21
ES2055314T3 (es) 1994-08-16
EP0382381B1 (de) 1993-05-26
JPH03504980A (ja) 1991-10-31
DE69001686T2 (de) 1993-09-02
IE64234B1 (en) 1995-07-26
ATE89737T1 (de) 1993-06-15
MY105798A (en) 1995-01-30
WO1990008554A1 (en) 1990-08-09
EP0455726A1 (de) 1991-11-13
ZA90600B (en) 1990-10-31
KR0137361B1 (ko) 1998-04-25
DE69001686D1 (de) 1993-07-01
NZ243953A (en) 1997-06-24
IE900318L (en) 1990-07-30
HK46196A (en) 1996-03-22
KR910700069A (ko) 1991-03-13
FI913625A7 (fi) 1991-07-30
PT92995A (pt) 1990-07-31
US5178855A (en) 1993-01-12
FI913625A0 (fi) 1991-07-30
AU5048890A (en) 1990-08-24
JPH0651640B2 (ja) 1994-07-06

Similar Documents

Publication Publication Date Title
EP0246322B1 (de) Behandlung einer krankheit vom aids-typ
EP0382381B1 (de) Behandlung von Leukozytstörungen mit GM-CSF
JP2805224B2 (ja) 血小板減少症治療剤
US5582822A (en) Treatment of leukemia using interleukin 2
US20100221274A1 (en) Method of administering a thymosin alpha 1 peptide
EP0231819B1 (de) Pharmazeutischer Stoff für die Behandlung von myelogener Leukämie
NZ259584A (en) Cancer treatment using interleukin 10 activated peripheral blood mononuclear cells optionally combined with il-10 alone or in combination with il-2 or alpha interferon (alpha-ifn), to stimulate peripheral blood mononuclear cells
US5620685A (en) Protecting agents from radiation hazards
AU8647491A (en) Uses of recombinant colony stimulating factor-1
AU630637B2 (en) Treatment of myelosuppression associated with acquired immune deficiency
Hu et al. Phase I study of recombinant human interferon beta in patients with advanced cancer
EP0405463A2 (de) Antikrebstherapie-Verbesserungsmittel
JP2002179588A (ja) チオレドキシンファミリーに属するポリペプチド類を含む炎症予防乃至治療剤
EP0661057A1 (de) Beschleuniger der proliferation hämatogoetischer zellen
WO1993000921A1 (en) Remedy for osteoporosis
Veldhuis et al. Interleukin 3: its role in the physiopathology of allergy and clinical use in oncology
WO1997021446A1 (fr) Composition pharmaceutique pour la protection des cellules souches hematopoietiques, et applications
US20050249698A1 (en) Synergistic effect of the osteogenic growth peptide and the granulocyte clony stimulating factor on haematogenesis
HK1132461B (en) Agent comprising g-csf for prevention and treatment of diabetic peripheral neuropathy
HK1111358A1 (en) Medium-chain length fatty alcohols as stimulators of hematopoiesis

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
RH1 Patent not in force